Cantor Fitzgerald reaffirmed its rating for Immunocore on July 20, 2026.
3 reports, 2 independent
Updated Aug 16
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald reaffirmed its rating for Immunocore on July 20, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Immunocore
UK business
Nothing else this week.
-
Cantor Fitzgerald
American financial services company
Related events
- Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.
- Briefing.com reported a rating change issued by Cantor Fitzgerald.
- Cantor Fitzgerald assigned a Neutral rating on Lucid stock on August 29, 2025.
- Cantor Fitzgerald maintained a Buy rating on Meta.
- Cantor Fitzgerald set an overweight rating for Enovix Corporation on October 8, 2026.